

APAS® INDEPENDENCE SALES TO HEALTH SERVICES LABORATORY, UK

First two APAS® instruments sold in United Kingdom

Adelaide, Australia, 18 May 2021: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the purchase of two APAS® Independence instruments by the Health Services Laboratory in the United Kingdom. The sales were completed directly by the Company's 50% owned joint venture company, Clever Culture Systems (**CCS**).

Key Points:

- **Health Services Laboratory (HSL) purchase two APAS® instruments for state-of-the-art Halo Facility, London**
- **HSL partnership includes the UK subsidiary of Sonic Healthcare Limited (ASX: SHL)**
- **Sale includes MRSA and Urine analysis modules**
- **Data from HSL's clinical evaluation to be presented at ECCMID Virtual Conference, July 2021**

CCS has finalised the sale of two APAS® instruments with MRSA and Urine analysis modules to the Health Services Laboratory following successful completion of clinical evaluations of both the MRSA and Urine analysis modules. The transaction was completed directly by CCS and falls outside the Beckman Coulter marketing arrangement. From a workflow perspective, APAS® Independence will perform screening of the high volume urine and MRSA specimens and will sit alongside the already installed BD Kiestra™ Total Lab Automation (TLA) solution. This is the first installation combining TLA with the APAS® workstation automation approach and is an example of how both solutions can provide benefits within the one laboratory.

HSL is located within the Halo building, part of London's life sciences hub, "Medcity". The laboratory is part of a public-private partnership and is a flagship UK laboratory and centre of excellence for The Doctors Laboratory (a subsidiary of Sonic Healthcare, ASX: SHL). Set up as a partnership between The Doctors Laboratory, Royal Free London NHS Foundation Trust and University College London Hospitals NHS Foundation Trust, the laboratory combines academic excellence with industry leading workflow efficiency.

The data generated from the clinical evaluation of MRSA completed by HSL has been accepted as a poster presentation for the upcoming meeting of European Congress of Clinical Microbiology and Infectious Diseases to be held virtually in July 2021. The poster publication will be one of five publications showcasing the APAS® technology at the conference providing an exciting body of clinical evidence helping to raise awareness and build the body of clinical evidence for the APAS® Independence with laboratories around the world.

Head of Department, Infection Sciences at HSL, Alan Spratt, said:

"We are really excited to be bringing the APAS® Independence into our lab. The performance that has been achieved during the evaluations of both the MRSA and Urine analysis modules exceeded our expectations and will enable us to better manage our culture plate workflow. We see this as cutting-edge technology, consistent with our goal of being a UK leader in clinical microbiology".

LBT CEO and Managing Director, Brent Barnes said:

"We are thrilled to complete the sale of two APAS® instruments to the Health Services Laboratory in the UK. Following the highly successful trial of the MRSA analysis module, the laboratory extended the scope of the study for their Urine workflow as well, presenting the opportunity for the sale of multiple instruments. This is a demonstration of the positive experience we have consistently seen from laboratories who have trialled our technology. As a technology leader in microbiology in the UK, this sale is also another key step to us building awareness and early adoption of the APAS® technology in the UK marketplace.

I would also like to thank Alan and the team at Health Services Laboratory for working with our teams completely remotely, during a time of COVID travel restrictions and associated pressures. This is a fantastic blueprint that demonstrates a new innovative service delivery model for the future. "

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com